A Phase 2a Study of HT-6184 in Subjects With IPSS-R Very Low, Low or Intermediate Risk MDS and Anemia

NCT07052006 · clinicaltrials.gov ↗

PHASE2

Phase

ACTIVE_NOT_RECRUITING

Status

37

Enrollment

INDUSTRY

Sponsor class

Conditions

Myelodysplastic Syndrome
Anemia in Myelodysplastic Syndromes

Interventions

DRUG: HT-6184

Sponsor

Halia Therapeutics, Inc.